Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Intravenous Dextrose Prevents Postoperative Nausea and Vomiting

By HospiMedica International staff writers
Posted on 05 Nov 2009
A new study claims that a simple intravenous (IV) administration of dextrose following surgery significantly reduces the occurrence of postoperative nausea and vomiting (PONV) and the need for antiemetic medication in the postoperative anesthesia care unit (PACU).

Researchers at Yale University School of Medicine (New Haven, CT, USA) conducted a double-blind randomized placebo-controlled trial of 56 healthy ambulatory surgery patients scheduled for gynecologic laparoscopic and hysteroscopic procedures. More...
The study patients were randomized to receive IV treatment with dextrose 5% in a Ringer's lactate solution (D5LF), while the control group received plain Ringer's lactate solution. Both treatments were given immediately after surgery and were continued as the patients were admitted to the PACU. All patients underwent a similar sevofluorane–vecuronium general anesthesia protocol and received one dose of an antiemetic 30 minutes before the end of anesthesia. The groups were similar in age, weight, anxiety level, previous PONV, previous surgery, nothing by mouth (NPO) status, anesthetic time, preoperative glucose, intraoperative nitrous oxide (NO) and narcotic use, and total weight-based fluid volume received. The researchers found that the patients who received the dextrose solution had significantly lower PONV scores 30 minutes after arriving in the PACU and at discharge, and lower overall PONV scores than the control group. Those in the dextrose group required half the amount of rescue antiemetic medications while in the PACU, and were discharged sooner. The study was presented at the American Society of Anesthesiologists annual meeting, held during October 2009 in New Orleans (LA, USA).

"We can prevent this with dextrose, which is universally available, inexpensive, and very practical," said study presenter Susan Dabu-Bondoc, M.D. "The use of dextrose is really a no-brainer."

Dextrose monohydrate, better known as glucose, is the major source of energy for living cells, and serves as a metabolic intermediate. It is a simple sugar, the right stereoisomer of aldohexose sugar, and is the main sugar that the body manufactures. Glucose can be produced from protein and fat, but is mainly derived from carbohydrates.

Related Links:

Yale University School of Medicine



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.